Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $10.91 Consensus Price Target from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received an average recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $10.9091.

TSHA has been the subject of a number of recent analyst reports. Wells Fargo & Company boosted their target price on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Citizens Jmp set a $8.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. The Goldman Sachs Group set a $11.00 price objective on Taysha Gene Therapies in a research report on Thursday, December 4th. Finally, Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $4.57 on Tuesday. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $6.02. The company has a market capitalization of $1.25 billion, a P/E ratio of -13.85 and a beta of 1.01. The firm has a 50 day moving average of $4.94 and a 200 day moving average of $4.36. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, CFO Kamran Alam sold 23,849 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the completion of the sale, the chief financial officer directly owned 1,443,786 shares of the company’s stock, valued at approximately $6,655,853.46. This represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $190,448.32. Following the completion of the transaction, the chief executive officer directly owned 2,908,257 shares in the company, valued at approximately $13,407,064.77. This represents a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 858,670 shares of company stock worth $3,995,000. 3.78% of the stock is owned by company insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently modified their holdings of the company. Intech Investment Management LLC raised its stake in Taysha Gene Therapies by 3.6% during the fourth quarter. Intech Investment Management LLC now owns 71,069 shares of the company’s stock valued at $391,000 after purchasing an additional 2,443 shares in the last quarter. Chicago Partners Investment Group LLC increased its holdings in shares of Taysha Gene Therapies by 1.5% in the 4th quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock worth $916,000 after buying an additional 2,504 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Taysha Gene Therapies by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock valued at $73,000 after acquiring an additional 2,765 shares during the last quarter. Virtus Investment Advisers LLC lifted its holdings in shares of Taysha Gene Therapies by 7.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock valued at $253,000 after acquiring an additional 3,008 shares during the last quarter. Finally, Xponance Inc. grew its position in Taysha Gene Therapies by 29.1% in the third quarter. Xponance Inc. now owns 16,575 shares of the company’s stock worth $54,000 after acquiring an additional 3,738 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.